Mechanisms of Diuretic Resistance in Heart Failure, Aim 3

Conditions

• Diuretic Resistance
• Heart Failure

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Ammonium Chloride — DRUG
  Participants will be randomized to receive either ammonium chloride or placebo. Participants will receive randomized drug in combination with IV bumetanide, bendroflumethiazide, and amiloride. Following a washout period, participants will be crossed over to the alternate drug.
• Placebo — DRUG
  Participants will be randomized to receive either ammonium chloride or placebo. Participants will receive randomized drug in combination with IV bumetanide, bendroflumethiazide, and amiloride. Following a washout period, participants will be crossed over to the alternate drug.

Study Details

Randomized double-blind placebo-controlled crossover study design

Key Dates

Start date

Jul 24, 2024

Status verified

Nov 2025

Primary completion

Mar 1, 2029

Completion

Mar 1, 2029

Study Design

Enrollment

50 participants (estimated)

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

OTHER

Arms

• Active Comparator: Ammonium chloride
  Participants will be randomized to ammonium chloride vs placebo. On Day 0 and 1, the participant will take ammonium chloride or placebo 75 mmol twice daily. On Day 2, the participant will take ammonium chloride 150 mmol or placebo once
• Placebo Comparator: Placebo
  Participants will be randomized to ammonium chloride vs placebo. On Day 0 and 1, the participant will take ammonium chloride or placebo 75 mmol twice daily. On Day 2, the participant will take ammonium chloride 150 mmol or placebo once

Primary Outcome Measure

Change of distal sodium reabsorption(ADRNa) between NH4Cl vs. placebo study visits [ Time Frame: Day 0 vs Day 1 ]

Central Contacts

• Veena Rao, PHD
  2037373571
  [email protected]

Locations (1)

Find similar trials in New Haven, CT

Related Studies

• Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
  Recruiting · Medtronic · Birmingham, Alabama
• Circulating Markers That Underlie the Transition From Compensated Hypertrophy to Heart Failure
  Recruiting · UConn Health · Farmington, Connecticut
• Real-Time Monitoring of Heart Failure Across the Yale New Haven Health System
  Recruiting · Yale University · New Haven, Connecticut
• Ertugliflozin in Chronic Heart Failure
  PHASE2 · Recruiting · Yale University · New Haven, Connecticut